Investor/trader focused primarily in the biopharma sector. Tweets are not investment advice and are not recommendations of any kind.
Toronto
- Tweets 61,590
- Following 92
- Followers 72,206
- Likes 618
Pinned Tweet
Big Pharma M&A set for mega year as patent expiries drive deal urgency. $XBI $IBB
If the current pace holds, 2026 biopharma M&A could top $250 billion, making it the #2 year on record after 2019’s $328 billion. #biotech
ca.finance.yahoo.com/news/bi…
4
11
54
39,012
$RNAZ Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Trial
prnewswire.com/news-releases…
4
3,671
$ABBV FDA Approves AbbVie's JUVMO (tavapadon) for Parkinson's Disease
prnewswire.com/news-releases…
2
3
4,347
$NKTR Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026.
New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata.
CC on Oct 1 at 8 AM
1
7
38
9,016
$MIRM Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
businesswire.com/news/home/2…
1
6
6,821
$SCYX Awarded BARDA Contract Providing Up to $214M in Non-Dilutive Funding for the Development of SCY-247
1
2
3,871
$KOD Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD
Zenkuda met the primary endpoint (p-value of 0.0007), demonstrating meaningful vision gains as well as rapid and sustained retinal drying with the majority of patients (54%) on 6-month dosing
ir.kodiak.com/news-releases/…
6
22
7,611
$MRK Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor.
SciBrunch to receive an upfront payment of $400M
businesswire.com/news/home/2…
2
4
25
13,526
$ACET Announces Positive Safety and Efficacy Data from Prula-cel Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR
businesswire.com/news/home/2…
1
4
14
6,430
$KOD Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD
Zenkuda met the primary endpoint (p-value of 0.0007), demonstrating meaningful vision gains as well as rapid and sustained retinal drying with the majority of patients (54%) on 6-month dosing
ir.kodiak.com/news-releases/…
2
11
30
14,700
$MNOV Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast). #Fail
investors.medicinova.com/new…
1
7
4,771
$MIRM CC on Monday to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta
3
2
12
6,967
$LLY FDA approves Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
investor.lilly.com/news-rele…
2
1
20
11,079
$KOD to Report Topline Data from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age AMD on Monday
1
2
20
11,803
$MIRM $INCY Announce FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
businesswire.com/news/home/2…
1
5
4,666
$FATE Announces Receipt of $15M California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
2
10
5,949
$ABSI Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201™ for Endometriosis
investors.absci.com/news-rel…
1
2
6
5,208